Your browser is no longer supported. Please, upgrade your browser.
PTLA Portola Pharmaceuticals, Inc. daily Stock Chart
Portola Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-4.77 Insider Own0.10% Shs Outstand56.32M Perf Week4.59%
Market Cap2.23B Forward P/E- EPS next Y-2.15 Insider Trans-62.30% Shs Float56.22M Perf Month3.10%
Income-269.00M PEG- EPS next Q-0.69 Inst Own91.70% Short Float9.17% Perf Quarter57.07%
Sales35.50M P/S62.87 EPS this Y-9.30% Inst Trans-0.79% Short Ratio4.72 Perf Half Y106.08%
Book/sh3.37 P/B11.76 EPS next Y39.60% ROA-70.20% Target Price41.32 Perf Year55.23%
Cash/sh5.66 P/C7.00 EPS next 5Y- ROE-96.20% 52W Range15.68 - 41.27 Perf YTD76.60%
Dividend- P/FCF- EPS past 5Y- ROI-112.00% 52W High-3.97% Beta1.38
Dividend %- Quick Ratio5.00 Sales past 5Y-14.60% Gross Margin- 52W Low152.74% ATR1.18
Employees163 Current Ratio5.00 Sales Q/Q211.40% Oper. Margin- RSI (14)65.70 Volatility2.13% 3.14%
OptionableYes Debt/Eq0.26 EPS Q/Q22.70% Profit Margin- Rel Volume0.60 Prev Close39.63
ShortableYes LT Debt/Eq0.26 EarningsMay 30 AMC Payout- Avg Volume1.09M Price39.63
Recom1.90 SMA203.91% SMA506.99% SMA20052.60% Volume0 Change0.00%
Feb-24-17Upgrade Oppenheimer Perform → Outperform
Jan-03-17Upgrade Citigroup Neutral → Buy
Dec-27-16Reiterated Credit Suisse Outperform $20 → $29
Aug-19-16Downgrade Citigroup Buy → Neutral
May-31-16Downgrade Credit Suisse Outperform → Neutral $33 → $30
Mar-28-16Reiterated Credit Suisse Outperform $47 → $34
Mar-28-16Downgrade Goldman Buy → Neutral $65 → $30
Dec-18-15Initiated Goldman Buy
Apr-17-17 09:01AM  Why Shares of Portola Pharmaceuticals Are Up Over 60% in 2017 Motley Fool
Apr-10-17 10:04AM  Losing Money on a Stock? Blame Your Brain Motley Fool
Apr-05-17 05:19PM  ETFs with exposure to Portola Pharmaceuticals, Inc. : April 5, 2017 Capital Cube
Apr-04-17 08:48AM  3 Hot Stocks to Buy in April Motley Fool
Mar-31-17 12:00PM  My 3 Top Biotech Stocks to Buy Now Motley Fool
Mar-16-17 09:22AM  Why Portola Pharmaceuticals Stock Is Already Up an Eye-Popping 72% This Year Motley Fool
Mar-13-17 10:11AM  Top Stocks That Are Already Crushing the Market in 2017 Motley Fool
Mar-09-17 08:15AM  Blog Coverage Keryx Biopharma Announced FDA Review Approval for Auryxia(R) Tablets Accesswire
Mar-07-17 04:05PM  Portola Pharmaceuticals Announces Betrixaban and AndexXa (andexanet alfa) Presentations at ACC.17 GlobeNewswire
09:21AM  Is Portola Pharmaceuticals Balance Sheet Safe? Motley Fool
Mar-06-17 01:58PM  ETFs with exposure to Portola Pharmaceuticals, Inc. : March 6, 2017 Capital Cube
Mar-03-17 11:17AM  Portola Pharmaceuticals, Inc. :PTLA-US: Earnings Analysis: Q4, 2016 By the Numbers : March 3, 2017 Capital Cube
Mar-02-17 10:42AM  Top Biotech Stocks With FDA Decisions in 2017 at Motley Fool
Mar-01-17 05:19PM  PORTOLA PHARMACEUTICALS INC Files SEC form 10-K, Annual Report +9.03%
08:00AM  Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences GlobeNewswire
05:02AM  Portola Pharmaceuticals posts 4Q loss
01:49AM  Edited Transcript of PTLA earnings conference call or presentation 28-Feb-17 9:30pm GMT
Feb-28-17 05:01PM  Why Is Portola Pharmaceuticals Stock Red Hot in 2017? at Motley Fool
04:56PM  PORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:30PM  Portola Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:05PM  Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update GlobeNewswire
07:07AM  Q4 2016 Portola Pharmaceuticals Inc Earnings Release - After Market Close
Feb-24-17 06:21AM  Portola Pharma upgraded by Oppenheimer
Feb-21-17 08:00AM  Portola Pharmaceuticals to Announce Fourth Quarter and Year-End 2016 Financial Results and Host Conference Call on Tuesday, February 28 GlobeNewswire
Feb-09-17 10:11AM  Portola Pharmaceuticals Inc (PTLA) Just Scored Twice In Quick Succession at Insider Monkey
Feb-08-17 09:46AM  Portola Pharmaceuticals Inks $150M Royalty Deal at Investopedia
08:00AM  FDA Informs Portola Pharmaceuticals at Mid-Cycle Review for Betrixaban That It Has Not Identified Issues that Require an Advisory Committee Meeting GlobeNewswire
Feb-06-17 08:19AM  Portola, HealthCare Royalty Partners Ink $150 Million Deal
Feb-03-17 09:32AM  Premarket Biotech Movers: Portola, Esperion, Medicines
08:42AM  PORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
08:00AM  Portola Pharmaceuticals Signs $150 Million Royalty Agreement with HealthCare Royalty Partners for Development and Commercialization of Andexanet Alfa GlobeNewswire
Jan-30-17 03:12PM  3 Biotech Stocks I'd Buy Right Now at Motley Fool
Jan-13-17 10:41AM  Why Portola Pharmaceuticals Crashed 56.4% In 2016 at Motley Fool
09:23AM  Biotech Premarket Movers: SGMO, IPXL, PTLA
Jan-12-17 03:54PM  3 Little-Known Pharmaceutical Companies to Put on Your Radar at Motley Fool
Jan-10-17 08:53AM  2 Top Stocks in Biotech at Motley Fool
Jan-03-17 05:41PM  My Worst Predictions for Biotech in 2016 at Motley Fool
08:00AM  Portola Pharmaceuticals to Webcast Corporate Update on January 10, 2017 GlobeNewswire
Dec-28-16 01:34PM  [$$] Portola Pharmaceuticals' Pivotal Year at
Dec-27-16 11:00AM  Biotech Poised for Rebound -9.10%
09:07AM  Portola Betrixaban Accepted for Review in U.S. & EU, Stock Up
Dec-23-16 05:35PM  Why Portola Pharmaceuticals Inc Stock Surged Higher Today at Motley Fool +33.80%
05:05PM  Why Portola Pharmaceuticals, Caesars Entertainment, and Cal-Maine Foods Jumped Today at Motley Fool
03:18PM  [$$] Portola Shares Surge on Application Acceptance at The Wall Street Journal
02:12PM  Portola Pharmaceuticals Announces FDA Accepts New Drug Application for Priority Review and EMA Validates Marketing Authorization Application for Oral, Factor Xa Inhibitor Anticoagulant Betrixaban GlobeNewswire
Dec-22-16 04:07PM  PORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an O
Dec-21-16 09:56AM  Portola Pharmaceuticals, Inc. Value Analysis (NASDAQ:PTLA) : December 21, 2016
Dec-20-16 10:36AM  Bristol-Myers Squibb Co (BMY) And Pfizer Inc. (PFE) Agree To $50 Million Loan To Portola Pharmaceuticals Inc (PTLA) at Insider Monkey
07:20AM  Portola Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PTLA-US : December 20, 2016
Dec-19-16 12:20PM  Portola Pharma Wins on Pfizer and Bristol-Myers Loan Agreement +7.55%
08:00AM  Portola Pharmaceuticals Enters into $50 Million Loan Agreement with Bristol-Myers Squibb and Pfizer for Continued Development of AndexXa (andexanet alfa) GlobeNewswire
Dec-15-16 05:18PM  PORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Dec-06-16 11:10AM  Is Portola Pharmaceuticals Inc (PTLA) Worthy of Your Portfolio? at Insider Monkey
Dec-02-16 03:46PM  3 Small-Cap Biotech Stocks That Could Double in 2017 at Motley Fool
Nov-28-16 08:00AM  Portola Pharmaceuticals Announces AndexXa (andexanet alfa), Betrixaban and Cerdulatinib Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition GlobeNewswire
Nov-14-16 04:15PM  Portola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits of Treating Acute Medically Ill Patients with Extended-Duration Betrixaban GlobeNewswire
Nov-08-16 03:32AM  Edited Transcript of PTLA earnings conference call or presentation 7-Nov-16 9:30pm GMT -12.87%
Nov-07-16 06:06PM  Portola Pharmaceuticals posts 3Q loss +5.67%
04:30PM  Portola Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:29PM  PORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:05PM  Portola Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update GlobeNewswire
08:00AM  Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data to be Presented at American Heart Association Scientific Sessions 2016 GlobeNewswire
07:07AM  Q3 2016 Portola Pharmaceuticals Inc Earnings Release - After Market Close
Nov-02-16 08:00AM  Portola Pharmaceuticals to Present at the Credit Suisse 25th Annual Healthcare Conference GlobeNewswire
Nov-01-16 08:00AM  Portola Pharmaceuticals Expands Clinical Collaboration Agreement with Daiichi Sankyo Worth Up to $25 Million to Develop AndexXa (andexanet alfa) in Germany GlobeNewswire
Oct-31-16 08:00AM  Portola Pharmaceuticals to Announce Third Quarter 2016 Financial Results and Host Conference Call on Monday, November 7 GlobeNewswire -9.24%
Oct-25-16 08:00AM  Portola Pharmaceuticals Submits New Drug Application to U.S. FDA for Betrixaban for Extended Duration Prophylaxis of Venous Thromboembolism in Acute Medically Ill Patients GlobeNewswire
Oct-13-16 06:07PM  Portola Pharmaceuticals Supports World Thrombosis Day Campaign to Increase Awareness of Risks of Blood Clots GlobeNewswire
Sep-27-16 09:54AM  3 Stocks That Could Make You Rich at Motley Fool
Sep-20-16 03:01PM  Forget Sarepta Therapeutics, Here Are 3 Other Biotech Stocks to Buy at Motley Fool
11:57AM  Portola Pharmaceuticals, Inc. Value Analysis (NASDAQ:PTLA) : September 20, 2016
Sep-19-16 03:00PM  After Losing Medivation, Who Is Gilead Going After Next? at Forbes
08:12AM  Portola Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PTLA-US : September 19, 2016
Sep-16-16 09:00PM  Underlying Risks in Speculative Biotechs; Trump Speaks, Bonds Slide : Best of Kass
Sep-13-16 10:50AM  ETFs with exposure to Portola Pharmaceuticals, Inc. : September 13, 2016
08:00AM  Portola Pharmaceuticals Announces Upcoming Data Presentations on AndexXa (andexanet alfa) at Neurocritical Care Society 2016 Annual Meeting GlobeNewswire
Sep-03-16 02:50PM  3 Biotech Stocks to Buy in September at Motley Fool
Aug-31-16 04:35PM  What Gives With Portola Pharmaceuticals? at Motley Fool
02:54PM  Heres Why Smart Money Investors Are Betting on Portola Pharmaceuticals at Insider Monkey
08:35AM  What's Up With Mylan's EpiPen Pricing? at Motley Fool
Aug-30-16 04:01AM  Portola Pharmaceuticals Announces Interim Results from Ongoing Phase 3b/4 ANNEXXA-4 Study of Factor Xa Inhibitor Antidote AndexXa (andexanet alfa) in Patients with Acute Major Bleeding GlobeNewswire
Aug-26-16 08:00AM  Portola Pharmaceuticals Announces Presentation of Interim Results from Phase 3b/4 ANNEXA-4 Study of AndexXa (andexanet alfa) at European Society of Cardiology 2016 Congress GlobeNewswire
Aug-24-16 02:09PM  Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Aug-22-16 07:48AM  Portola IndexXa's Regulatory Application Validated in the EU
Aug-21-16 10:05AM  6 Companies That Destroyed Shareholders Last Week at 24/7 Wall St.
08:38AM  3 Stocks That Could Double Your Money at Motley Fool
Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily inhibitor of Factor Xa that is in Phase III clinical stage for extended duration VTE prophylaxis in acute medically ill patients for 35 days of in-hospital and post-discharge use; Andexanet alfa, a recombinant protein, which is in Phase III and IV stages for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, an orally available dual kinase inhibitor, which is in Phase IIa clinical stage for hematologic, blood, cancers, and inflammatory disorders. It also develops Syk-selective inhibitors in pre-clinical stage for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; and Dermavant Sciences GmbH. The company was founded in 2003 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lis WilliamChief Executive OfficerApr 11Sale36.066,750243,4054,730Apr 11 04:34 PM
Fu TaoEVP, CBOApr 10Sale36.971,09740,5560Apr 11 04:31 PM
HOMCY CHARLES JDirectorMar 15Option Exercise5.0050,000250,00050,000Mar 16 06:18 PM
Dier MardiExecutive VP and CFOMar 15Option Exercise7.6310,23578,0955,935Mar 16 06:45 PM
Dier MardiExecutive VP and CFOMar 15Sale40.0210,235409,6050Mar 16 06:45 PM
HOMCY CHARLES JDirectorMar 15Sale40.0650,0002,003,0000Mar 16 06:18 PM
HOMCY CHARLES JDirectorMar 01Option Exercise5.0025,000125,00025,000Mar 03 05:02 PM
HOMCY CHARLES JDirectorMar 01Sale37.5025,000937,5000Mar 03 05:02 PM
Dier MardiExecutive VP and CFOAug 01Option Exercise3.3015,15250,00215,152Aug 01 08:39 PM
Lis WilliamChief Executive OfficerMay 02Sale23.865,675135,40618,333May 03 07:23 PM